Spinal Manipulation and Dry Needling vs. Botox Injections in the Management of Chronic Migraine: A Randomized Non-Inferiority Controlled Trial Protocol

LAWRENCE RAMISCAL, PT, DPT, PH.D.

BOARD-CERTIFIED CLINICAL SPECIALIST IN ORTHOPAEDIC PHYSICAL THERAPY FELLOW, AMERICAN ACADEMY OF ORTHOPAEDIC MANUAL PHYSICAL THERAPISTS ASSISTANT PROFESSOR

DIRECTOR OF RESEARCH AND FACULTY DEVELOPMENT



Migraine

2: Rank in the world's causes of disability

- ► Global Burden is Disease study in 2019 (Steiner et al., 2020)
 - Following low back pain
 - #1 in young women (15-49 years)

Types

- Episodic (<15 headache days/month)</p>
- ▶ Chronic (≥ 15 headache days/month)
 - Less common but most disabling (more headache days) (Katsarava et al., 2012)

High prevalence of neck pain (Al-Khazali et al., 2022)

Cervical musculoskeletal disorders (Liang et al., 2019)



Treatment Options

Oral Medications (American Headache Society)

- Poor efficacy and tolerability
- Low treatment persistence
- Potential for overuse (Hepp et al., 2015, 2017)

Targeted Conservative Alternatives

- Local injections
 - Botulinum toxin A (Botox®)
- Physical Therapy
 - Spinal manipulation
 - Dry needling
 - * High prevalence of neck pain in migraine



Botox®

1st and only FDA-approved preventive specific for chronic migraine

- Superior to placebo
 - ► Meta-analysis of 10 years of real-world data (Lanteri-Minet et al., 2022)
- Approved protocol since 2010 (Blumenfeld et al., 2010)
 - > 2 rounds; 3 months apart
- Selected facial and neck muscles

Disadvantages

- Adverse events
 - eyelid ptosis and muscle weakness
 - Rare complications: dysphagia, botulism, and sometimes death (systematic spread of the toxin)
- Cost
 - \$3,000 (unaffordable, decreased compliance)



Physical Therapy: Spinal Manipulation (SM)

Effective for headaches

- Cervicogenic type (Bini et al., 2022; Fernandez et al., 2020)
 - Presence of neck pain from cervical joint impairments

Types

- Thrust or Non-thrust
 - Upper cervical, cervicothoracic
- **Relatively safe** (Peters et al., 2022; Swait & Finch, 2017)
 - Benign adverse events
 - symptom aggravation, stiffness, lightheadedness
 - Extremely rare complications
 - cervical artery dissection and disc herniation exacerbation



Physical Therapy: Dry Needling (DN)

Effective for headaches

- Cervicogenic type (Pourahmadi et al., 2021; Vázquez-Justes et al., 2022)
 - Presence of neck pain from muscular trigger points

Solid filiform needle

- FDA Class II medical device
- Selected facial and neck muscles
- Relatively safe (Boyce et al., 2020; Gattie et al., 2020)
 - Benign adverse events
 - pain during and after treatment, bleeding, and bruising
 - Extremely rare complications
 - prolonged symptom aggravation, fainting, and forgotten needles during dry needling



Aim Compare the effectiveness of SM and DN as non-inferior to Botox[®] in patients with chronic migraine

Hypothesis

- SM and DN are at least as good (not unacceptably worse) as Botox®
- However, SM would be more effective than DN

Theory

- Universal mechanism: Inhibition of inflammatory mediators affecting the trigeminocervical complex (Aoki AR, 2005; Bialosky et al., 2018; Dommerholt J, 2011)
- Botox® is the assumed treatment standard
 - FDA approval and abundance of evidence
- SM and DN (though not superior) may be potential alternatives
 - Cost-effectiveness and relative safety
- SM has more evidence; DN is relatively new

Ethics

No placebo



Population

- Adult patients diagnosed with chronic migraine (International Classification of Headache Disorders, 2018)
- Veterans Affairs (VA) healthcare system in the Southeast region

Intervention

- Active Control (C): Botox®
 - **FDA approved protocol** (Blumenfeld et al., 2010)
 - > 2 rounds; 3 months apart
- Test Treatment 1 (T1): SM
 - > Thrust and non-thrust to the upper cervical and cervicothoracic regions (impairment-based) (Dunning et al., 2016)
 - Frequency: 1/week x 4 weeks (4 sessions); 2 rounds; 2 months apart
- Test Treatment 2: DN
 - Facial and neck muscles (impairment-based) (Mousavi-Khatir et al., 2021)
 - Frequency: 1/week x 4 weeks (4 sessions); 2 rounds; 2 months apart



Endpoints (change from baseline) (International Headache Society Guidelines, Tassorelli et al., 2018)

- Primary
 - # Headache days/month
- Secondary
 - Intensity, medication usage, Beck Depression Inventory, Global Rating of Change, Migraine Functional Impact Questionnaire, Headache Disability Index, Migraine Disability Assessment, Headache Impact Test-6, Neck Disability Index



Study Protocol Flow Diagram

4-Week Baseline Phase

Headache diary to assess compliance

Eligibility

- Age 18-65 years
- Chronic migraine
- No contraindication to Botox, cervical manipulation, and dry needling


Randomization

• Stratification

Treatment Groups



Treatment Flow Diagram





Research Design Statistical Analyses

Power Analysis

- Total sample size = 78 (26/group) (Cleveland Clinic Sample Size Calculator, Wang and Ji, 2020)
 - Non-inferiority margin (M) (US FDA Non-Inferiority Guidance., 2016)
 - Primary endpoint systematic review with meta-analysis (Lanteri-Minet et al., 2022)
 - Mean difference of random effects model
 - -10.4 (-11.35, -9.46) headaches days change from baseline
 - \blacktriangleright M₁ = lower bound of the 95% confidence interval (CI)
 - M₂ = 50% discount of M₁ combined with the largest clinically acceptable difference (degree of inferiority) of T compared to C (effect size of 0.8)
 - Power = 0.8
 - \blacktriangleright Type 1 error rate = 0.5
 - \blacktriangleright Attrition rate = 20%



Research Design Statistical Analyses

Data Analysis

- Inferential Statistics
 - Mixed-model analysis of variance (each outcome)
 - Multiple comparison procedures
 - Between subjects factors (treatment groups)
 - Within subjects factors (time)
 - Effect sizes
- Clinical Statistics
 - Intention-to-treat analysis
 - Per-protocol analysis
 - Number needed to treat



IRB approval

VA health system

Trial registration

Clinicaltrials.gov

Level of pragmatism

Pragmatic-Explanatory Continuum Indicator Summary (PRECIS-2) (Loudon et al., 2015)

Reporting

Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement (Piaggio et al., 2012)

